Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 31;14(1):2592.
doi: 10.1038/s41598-024-52482-w.

Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography

Affiliations

Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography

Xiangjun Qi et al. Sci Rep. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, whose severe form is associated with oxidative stress. Vitamin E as an antioxidant has a protective potential in NAFLD. Whether dietary intake of vitamin E, supplementary vitamin E use, and total vitamin E have a preventive effect on NAFLD requires investigation. A cross-sectional study used data from the National Health and Nutrition Examination Survey (2017-2020) was conducted. Vitamin E intake, including dietary vitamin E, supplementary vitamin E use, and total vitamin E, was obtained from the average of two 24-h dietary recall interviews. The extent of hepatic steatosis was measured by liver ultrasound transient elastography and presented as controlled attenuated parameter (CAP) scores. Participants were diagnosed with NAFLD based on CAP threshold values of 288 dB/m and 263 dB/m. The statistical software R and survey-weighted statistical models were used to examine the association between vitamin E intake and hepatic steatosis and NAFLD. Overall, 6122 participants were included for NAFLD analysis. After adjusting for age, gender, race, poverty level index, alcohol consumption, smoking status, vigorous recreational activity, body mass index, abdominal circumference, hyperlipidemia, hypertension, diabetes, and supplementary vitamin E use, dietary vitamin E was inversely associated with NAFLD. The corresponding odds ratios (OR) and 95% confidence intervals (CI) of NAFLD for dietary vitamin E intake as continuous and the highest quartile were 0.9592 (0.9340-0.9851, P = 0.0039) and 0.5983 (0.4136-0.8654, P = 0.0091) (Ptrend = 0.0056). Supplementary vitamin E was significantly inversely associated with NAFLD (fully adjusted model: OR = 0.6565 95% CI 0.4569-0.9432, P = 0.0249). A marginal improvement in total vitamin E for NAFLD was identified. The ORs (95% CIs, P) for the total vitamin E intake as continuous and the highest quartile in the fully adjusted model were 0.9669 (0.9471-0.9871, P = 0.0029) and 0.6743 (0.4515-1.0071, P = 0.0538). Sensitivity analysis indicated these findings were robust. The protective effects of vitamin E significantly differed in the stratum of hyperlipidemia (Pinteraction < 0.05). However, no statistically significant results were identified when the threshold value was set as 263 dB/m. Vitamin E intake, encompassing both dietary and supplemental forms, as well as total vitamin E intake, demonstrated a protective association with NAFLD. Augmenting dietary intake of vitamin E proves advantageous in the prevention of NAFLD, particularly among individuals devoid of hyperlipidemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The overall design of the study and participants filtration. Abbreviation: NHANES, National Health and Nutrition Examination Survey.
Figure 2
Figure 2
Weighted association between vitamin E intake and controlled attenuated parameter. Non-adjusted model: no covariates were adjusted. Minimally adjusted model: age and gender were adjusted. Fully adjusted model: age, gender, race, poverty level index, alcohol consumption, smoking status, moderate to vigorous recreational activity, body mass index, abdominal circumference, hypertension, diabetes and hyperlipidemia were adjusted. Supplementary vitamin E was also adjusted when exposure was to dietary vitamin E and total vitamin E. Abbreviation: CI, confidence interval.
Figure 3
Figure 3
Weighted association between dietary vitamin E intake and non-alcoholic fatty liver disease at controlled attenuated parameter 288 dB/m. Non-adjusted model: no covariates were adjusted. Minimally adjusted model: age and gender were adjusted. Fully adjusted model: age, gender, race, poverty level index, alcohol consumption, smoking status, moderate to vigorous recreational activity, body mass index, abdominal circumference, hypertension, diabetes, hyperlipidemia and supplementary vitamin E were adjusted. Sensitivity analysis was implemented by excluding patients who never drank. Abbreviation: OR, odds ratio; CI, confidence interval.
Figure 4
Figure 4
Weighted association between total vitamin E intake and non-alcoholic fatty liver disease diagnosed at controlled attenuated parameter 288 dB/m. Non-adjusted model: no covariates were adjusted. Minimally adjusted model: age and gender were adjusted. Fully adjusted model: age, gender, race, poverty level index, alcohol consumption, smoking status, moderate to vigorous recreational activity, body mass index, abdominal circumference, hypertension, diabetes and hyperlipidemia were adjusted. Supplementary vitamin E was also adjusted when exposure was to total dietary vitamin E. Sensitivity analysis was implemented by excluding patients who never drank. Abbreviation: OR, odds ratio; CI, confidence interval.

Similar articles

Cited by

References

    1. Younossi ZM, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. Transplantation. 2019;103(1):22–27. doi: 10.1097/TP.0000000000002484. - DOI - PubMed
    1. Younossi Z, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15(1):11–20. doi: 10.1038/nrgastro.2017.109. - DOI - PubMed
    1. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431. - DOI - PubMed
    1. Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J. Intern. Med. 2022;292(2):190–204. doi: 10.1111/joim.13531. - DOI - PMC - PubMed
    1. Bellanti F, et al. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic. Biol. Med. 2017;111:173–185. doi: 10.1016/j.freeradbiomed.2017.01.023. - DOI - PubMed

MeSH terms